The WISDOM study: a new approach to screening can and should be tested Laura EssermanMartin EklundMichael Plaza Editorial 16 September 2021 Pages: 593 - 598
Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers Peter SavasRoberto SalgadoSherene Loi Review 06 September 2021 Pages: 599 - 606
Long non-coding RNA ARHGAP5-AS1 inhibits migration of breast cancer cell via stabilizing SMAD7 protein Chen-Long WangJing-Chi LiQian Zhao Preclinical study Open access 09 August 2021 Pages: 607 - 619
Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer Maryam AlthobitiKhloud A. El-sharawyEmad A. Rakha Preclinical study Open access 28 August 2021 Pages: 621 - 630
Patient and provider determinants of breast cancer screening among Ontario women aged 40–49: a population-based retrospective cohort study Michelle B. NadlerNoah IversEitan Amir Preclinical study 19 August 2021 Pages: 631 - 640
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations Jing XuTanya E. KeenanSteven J. Isakoff Clinical trial 20 August 2021 Pages: 641 - 651
Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution’s experience in Korea Yeon Hee ParkVassiliki KarantzaMark Marsico Clinical trial 06 September 2021 Pages: 653 - 663
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens Ming Shen DaiYin Hsun FengMing Feng Hou Clinical trial Open access 23 September 2021 Pages: 665 - 676
Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women D. Gareth EvansSacha J. HowellAnthony Howell Clinical trial Open access 26 July 2021 Pages: 677 - 687
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population Michelino De LaurentiisSimona BorstnarClaudio Zamagni Clinical trial Open access 19 August 2021 Pages: 689 - 699
Utilization and predictors of postmastectomy radiation receipt in an Oncology Center in Zimbabwe Fallon E. ChipidzaMelinda MushongaShekinah N. Elmore Clinical trial 13 August 2021 Pages: 701 - 709
Correlation between MRI morphological response patterns and histopathological tumor regression after neoadjuvant endocrine therapy in locally advanced breast cancer: a randomized phase II trial Joana ReisOwen ThomasJonn Terje Geitung Clinical trial Open access 06 August 2021 Pages: 711 - 723
Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer Huiping LiGuohong SongYouzhi Tong Clinical trial Open access 14 August 2021 Pages: 725 - 736
Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy Sung Jun MaLucas M. SerraAnurag K. Singh Epidemiology 14 September 2021 Pages: 737 - 745
Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer Ji-Yeon KimEunjoo JeonYoung-Hyuck Im Epidemiology 05 July 2021 Pages: 747 - 757
Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy Ye Won JeonHyung Soon ParkHyun A Kim Epidemiology 20 July 2021 Pages: 759 - 768
Associations between frailty and cancer-specific mortality among older women with breast cancer Connie H. YanChandler ColemanGregory S. Calip Epidemiology 09 July 2021 Pages: 769 - 779
Symptoms associated with comorbid diabetes among breast cancer survivors Steven S. CoughlinDeepak Nag Ayyala Epidemiology 09 July 2021 Pages: 781 - 786
Fatigue and resting-state functional brain networks in breast cancer patients treated with chemotherapy Biniam Melese BekeleMaryse LuijendijkLinda Douw Epidemiology Open access 14 July 2021 Pages: 787 - 796
Clinical outcomes and prognostic biomarkers among pregnant, post-partum and nulliparous women with breast cancer: a prospective cohort study Katarzyna J. JerzakNechama LiptonEllen Warner Epidemiology 27 July 2021 Pages: 797 - 806
Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan Lei LeiHan-Ching ChanSkye Hung-Chun Cheng Epidemiology 19 July 2021 Pages: 807 - 815
Improved risk estimation of locoregional recurrence, secondary contralateral tumors and distant metastases in early breast cancer: the INFLUENCE 2.0 model Vinzenz VölkelTom A. HuetingSabine Siesling Epidemiology Open access 02 August 2021 Pages: 817 - 826
Risk factors for breast cancer subtypes among Black women undergoing screening mammography Tara M. Friebel-KlingnerSarah EhsanAnne Marie McCarthy Epidemiology 03 August 2021 Pages: 827 - 835
Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy Sue Zann LimGrace KusumawidjajaVeronique Kiak Mien Tan Epidemiology 03 August 2021 Pages: 837 - 843
Impact of molecular subtype and race on HR+, HER2− breast cancer survival Sonya ReidDiane HaddadTuya Pal Epidemiology 31 July 2021 Pages: 845 - 852
